肺癌免疫学检测及临床应用的研究

Immunol ogical Determinations of Lung Cancer Markers and Their Clinical Application

用标志物神经特异性烯醇化酶(NSE)、癌胚抗原(CEA)、铁蛋白(Ft)以及PBL亚群技术对肺癌及胸部疾病患者(188例)进行测定,并对60例肺癌患者进行治疗前后的对比观察。表明:1.血清NSE水平:肺癌(LC)组与正常(NC)组和良性胸部疾患组(BD),小细胞肺癌(SCLC)与非小细胞肺癌(NSCLC)组比较;CEA水平:LC组与NC组和BD组,SCLC组与NSCLC组相比:Ft水平:LC组与NC组对比;差异均有显著性(均P<0.01)。PBL亚群,LC与NC组比较各亚群均有显著性差异(均P<0.01)。2.标志物单项测定的阳性率NSE、CEA和Ft分别是66.67％、56.67％和46.66％,而三项联合测定的阳性率增至89.88％,差异有显著性。联合测定和NSE及PBL亚群的动态观察,对LC的诊断和预后判断有重要临床意义。

The 188 patients with lung cancer or other chest disease were demonstrated by using tumor markers as follows: neuron-specific enolase(NSE) ,carcmoembryonic antigen(CEA) ,ferntin(Ft )and periph- eral blood lymphocyte (PBL)subpopulation technique. In the meantime, 60 patients with lung cancer (LC)were observed pre-and post-treatment. The results were as follows : (1)There were significant differences (.P<0.01) when the serum NSE.CEA of LC were compared with those of controls and benign chest disease,and when small cell lung cancer (SCLC) were compared with non-small cell lung cancer (NSCLC). There were also significant differences when the serum Ft and PBL subsets of LC compared with NC- (2) The positive rate that was examined for single NSE,CEA,Ft was 66. 67%.56. 67% and 46- 66% respectively,if those tumor markers were combined as one positive standard,the sensitivity will raise to 89. 88%,there were signifeant differences between them (P<0. 01). The result suggested : assay the serum NSE.CEA and Ft at sametime and observed the NSE,PBL subsets pre- and post-treatment had a great clinical value when they are used to diagnase lung cancer and judge prognosis.